Stay alert, beware of scamsters - know more

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open136.75
High136.75
Low134.05
Prev. Close136.76
Avg. Traded Price134.77
Volume83,929

MARKET DEPTH

info2
Total bid115184.00
Total ask150857.00
OrdersQtyBid
3472134.06
2101134.05
151134.04
1500134.03
111134.02
AskQtyOrders
134.216
134.22137
134.23133
134.26131
134.27215

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

129.82a day ago
136.5617 hours ago
arrow

LOWER/UPPER CIRCUITS

106.23
159.33
arrow
Camlin Fine Sciences Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Revenue,rose 4.23%, in the last year to ₹1,752.1 Cr. Its sector's average revenue growth for the last fiscal year was 8.63%.
noteAnnual Net Profit,rose 119.87% in the last year to ₹27.63 Cr. Its sector's average net profit growth for the last fiscal year was 32.87%.
noteQuarterly Net profit,rose 12,282.58% YoY to ₹88.2 Cr. Its sector's average net profit growth YoY for the quarter was -9.39%.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 12.4%
Net profit growth 5Y CAGR : %

About the Camlin Fine Sciences Limited (CFS) 

Camlin Fine Sciences Limited (CFS) is an Indian speciality chemicals company incorporated on November 30, 1993. The company is engaged in the research, development, manufacturing and marketing of speciality ingredients, aroma ingredients, performance chemicals and additive blends used across food, animal nutrition, pet food, pharmaceutical, petrochemical and industrial sectors worldwide.

Its key product lines include:

  • Shelf-Life Solutions – TBHQ, BHA, BHT, Ascorbyl Palmitate and synergistic antioxidant blends

  • Aroma Ingredients – Vanillin, Ethyl Vanillin and Natural Vanillin

  • Performance Chemicals – Hydroquinone (HQ), Catechol, MEHQ, TBC, Guaiacol and Veratrole

  • Health & Wellness – algae-based Omega-3 products

CFS operates two manufacturing plants in India—Boisar (Tarapur) in Thane district and Dahej SEZ II in Bharuch, Gujarat. It also maintains an R&D Centre at Boisar and an Application Lab at Wagle Estate, Thane. The registered office is located in Mumbai.

CFS has built a significant global footprint through blending and manufacturing operations across India, Mexico, Brazil, USA and Europe. The company is also recognised as one of the world’s largest producers of Methyl Vanillin. It serves 28 Indian states/UTs and 56 countries, with exports contributing 64.84% of turnover in the reported year.

As on March 31, 2025, the Group comprised 21 subsidiaries (including step-down subsidiaries) and 1 associate of a step-down subsidiary.

Business Segments

Segment Contribution (Turnover Mix):

  • Specialty Ingredients: 77%

  • Performance Chemicals: 12%

  • Aroma Ingredients: 11%

Geographical Mix:

  • Exports: 64.84% of turnover

  • Domestic: 35.16%

Key Management

  • Ashish S. Dandekar – Chairman & Managing Director

  • Nirmal V. Momaya – Managing Director

  • Arjun Dukane – Executive Director – Technical

  • Santosh Parab – Chief Financial Officer

  • Rahul Sawale – Company Secretary & VP – Legal

Latest Updates

Strategic Acquisitions & Consolidation

  • June 11, 2024: Mexican subsidiary Dresen Quimica SAPI de CV acquired 100% of Vitafor Invest NV (Belgium) to strengthen its presence in European and African feed/pet food markets.

  • February 24, 2025: Entered a Share Purchase Agreement to acquire a majority stake in Vinpai S.A. (France), along with a €3.3 million convertible bond investment. The transaction involves a share swap followed by a mandatory tender offer at €3.60 per share (subject to approvals).

  • Reverse merger: CFS De Mexico Blends S.A.P.I. de C.V. merged into Dresen Quimica S.A.P.I. de C.V., effective February 28, 2025.

Divestments & Discontinuations

  • Decision to close and liquidate CFS Wanglong Flavors (Ningbo) Co. Ltd., China, with impairment charges recognised.

  • Production of Diphenols at CFS Europe S.p.A., Italy discontinued due to economic viability; results disclosed as discontinued operations.

Financing & Capital Support

  • Challenging market conditions mitigated by shareholder support through a rights issue and interim NCD funding.

  • Employee Stock Option Plan (2021) amended on April 23, 2025; no new grants issued during the year.

Ratings

India Ratings downgraded CFS by two notches:

  • IND BBB/Negative (term loan)

  • IND BBB/Negative / IND A3+ (fund-based limits)

  • IND A3+ (non-fund-based limits)

Operations & Sustainability

  • Transition plans to shift power at Tarapur and Dahej to renewable (hybrid wind–solar) sources.

  • Energy-efficiency upgrades implemented across both plants.

  • Setting up a co-generation plant at Tarapur for operational resilience.

Technology & Partnerships

  • Strategic collaboration with Lockheed Martin to deploy long-duration flow battery technology, strengthening energy resilience and enabling expanded renewable energy usage.
personal

Grow your wealth with more research recommendations

+91

Frequently Asked Questions

For Q4 FY26, Camlin Fine Sciences Ltd reported: Revenue (Net Sales): ₹1835.16 Cr - Down -16.17% year-on-year from ₹2189.21 Cr in Q3 FY26. Net Income (PAT): ₹-56.50 Cr - Up -56.53% year-on-year from ₹-129.97 Cr in Q3 FY26.

As of 07 Jul 2026, the share price of Camlin Fine Sciences Ltd is ₹135.99 on the NSE and ₹134.70 on the BSE. The stock opened at ₹133.00, touched a high of ₹136.75 and a low of ₹129.82 during today's session.

Over the last 6 months, Camlin Fine Sciences Ltd has given a return of -12.17%. The stock was priced at ₹151.18 on 07 Jan 2026 and has Fallen to ₹135.99 as of 07 Jul 2026, a change of ₹15.19 per share.

Camlin Fine Sciences Ltd has delivered -55.64% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹305.40 on 09 Jul 2025 and a 52-week low of ₹96.21 on 30 Mar 2026. It is currently trading at ₹135.99 as of 07 Jul 2026.

The all-time high (ATH) for Camlin Fine Sciences Ltd was ₹327.53, recorded on 27 Jun 2025. At the current price of ₹135.99, the stock is trading 58.48% below its all-time high. The all-time low recorded was ₹32.88 on 25 Mar 2020.

Camlin Fine Sciences Ltd has delivered a -32.87% absolute return over the past 5 years, equivalent to a CAGR of -7.66% per annum. The stock was priced at ₹202.58 in Jul 2021 and has fallen to ₹135.99 as of 07 Jul 2026. An investment of ₹1,00,000 in Camlin Fine Sciences Ltd five years ago would be worth ₹67,130.00 today.

No,Camlin Fine Sciences Ltd has not declared any dividend over the past 5 years. The company paid a total dividend of N/A per share between FY2022 and FY2026, with the most recent dividend of ₹0.45 per share for May 16, with an ex-dividend date of 28 Jul 2016. At the current market price of ₹135.99, the trailing dividend yield of Camlin Fine Sciences Ltd stands at 0.45%.

The intraday high for Camlin Fine Sciences Ltd on the NSE today (07 Jul 2026) was ₹136.75. This compares to the 52-week high of ₹305.40 recorded on 09 Jul 2025. Today's high was -55.22% below the 52-week high.

The intraday low for Camlin Fine Sciences Ltd on the NSE today was ₹129.82. The stock's 52-week low stands at ₹96.21, recorded on 30 Mar 2026. Today's low is 34.93% above the 52-week low, indicating the stock is trading well above its yearly lows.

Camlin Fine Sciences Ltd has delivered a return of 27.85% over the last 3 months. The stock was trading at ₹103.86 on 07 Apr 2026 and is currently at ₹135.99 as of 07 Jul 2026, reflecting a Gain of ₹32.13 per share over this period.

+91
Offer Banner Trigger
Offer Banner

Open a FREE Demat Account

+91